Beta-Caryophyllene / PPARγ Cancer Research Results

BCP, Beta-Caryophyllene: Click to Expand ⟱
Features:

β-Caryophyllene is a dietary sesquiterpene and CB2 agonist with preclinical anticancer evidence, including apoptosis induction, reduced proliferation, anti-angiogenesis, reduced invasion/migration, and chemo/radio-sensitization. Evidence is promising but remains mainly in-vitro and animal-based; clinical cancer validation is lacking.
-naturally occurring sesquiterpene found in many plant essential oils: black pepper, clove oil ...
-binds selectively to the CB2 receptors(modulates up) and not the CB1 receptor, which makes it non-psychoactive and therapeutically appealing.

-Ylang-Ylang leaves have been found to contain the highest concentration of BCP (52%)
-black pepper, 30% BCP in its fruit-derived essential oil.
-leaves of the tropical tree Spondias pinnata yield 49.9% BCP
-Pimpinella kotschyana, a Mediterranean herb, was found to contain 49.9% BCP in its seeds
-Sumac fruits contain 34.3% BCP
-clove buds contain 20–30% BCP in their essential oil
-certain cannabis strains, flowers can produce BCP concentrations of approximately 30%
-sugar apples leaves contain 22.9% BCP

Beta-Caryophyllene — β-Caryophyllene is a plant-derived bicyclic sesquiterpene hydrocarbon and dietary cannabinoid with selective functional agonism at cannabinoid receptor type 2. It is formally classified as a natural sesquiterpene terpene, food flavoring compound, and investigational phytochemical adjunct rather than an approved anticancer drug. Standard abbreviations include BCP, β-CP, and sometimes trans-caryophyllene. It occurs in multiple essential oils, especially black pepper, clove, copaiba, oregano, hops, rosemary, and Cannabis sativa chemotypes, but its database identity should be the purified compound rather than a whole-oil product.

Primary mechanisms (ranked):

  1. CB2-centered anti-inflammatory and immunomodulatory signaling, with low CB1 activity and therefore no intrinsic THC-like psychoactive classification.
  2. Suppression of pro-survival oncogenic signaling, especially PI3K/Akt/mTOR, STAT3, NF-κB, and related proliferation or survival pathways in cancer models.
  3. Induction of mitochondrial apoptosis through Bax/Bcl-2 shift, caspase activation, mitochondrial stress, and cell-cycle arrest in several cancer cell lines.
  4. Anti-angiogenic and anti-migratory activity, including inhibition of endothelial migration, tube formation, VEGF-linked responses, EMT, invasion, and metastasis-associated phenotypes.
  5. Chemosensitization, mainly preclinical, reported with cisplatin and other cytotoxic or targeted agents; mechanism appears context-dependent and partly linked to apoptosis and resistance-pathway modulation.
  6. Radiosensitization, currently preliminary and model-dependent, with recent colorectal cancer cell evidence involving PPARγ-mediated apoptosis.
  7. ROS/NRF2 modulation is secondary and context-dependent: BCP can promote oxidative stress in cancer-cell apoptosis models, while in normal injury models it more often shows cytoprotective antioxidant and NRF2-linked effects.

Bioavailability / PK relevance: BCP is highly lipophilic and formulation-sensitive; oral exposure is limited and variable with conventional dosing, while self-emulsifying lipid formulations can substantially improve human systemic exposure. PK relevance is high because many in-vitro anticancer concentrations are unlikely to be reproduced by normal dietary intake.

Delivery constraints: The key delivery constraints are volatility, hydrophobicity, oxidation/stability, low aqueous solubility, food-matrix dependence, and the likely need for lipid, nanoemulsion, SEDDS, or other formulation strategies if systemic pharmacology is the goal.

In-vitro vs systemic exposure relevance: Most anticancer assays use micromolar-to-high-micromolar or µg/mL concentrations; these should be interpreted cautiously because common in-vitro levels likely exceed exposures achievable from culinary intake. Formulated oral BCP may improve exposure, but clinical anticancer target engagement has not been established.

Clinical evidence status: Preclinical oncology evidence is moderate and spans cell, endothelial, and animal models; human evidence is small and mostly non-oncology or PK-focused. No validated clinical cancer efficacy evidence was found. Best database status is preclinical / investigational adjunct, with possible chemosensitizer and anti-angiogenic tags marked as preclinical.

Beta-Caryophyllene Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 CB2 receptor signaling CB2 engagement may shift inflammatory and survival signaling ↓ (context-dependent) CB2-mediated inflammation ↓ with low CB1 psychoactivity R/G Anti-inflammatory and immunomodulatory signaling Core pharmacologic identity of BCP; direct anticancer dependence on CB2 varies by model.
2 PI3K Akt mTOR STAT3 survival signaling PI3K/Akt/mTOR ↓; STAT3 ↓; proliferation ↓; survival ↓ Usually cytoprotective or neutral at lower exposure (context-dependent) R/G Growth suppression and apoptosis sensitization Central anticancer axis across bladder, ovarian, lung, and other cell models; not yet clinically validated.
3 Mitochondrial apoptosis Bax ↑; Bcl-2 ↓; caspase-3 ↑; mitochondrial stress ↑; apoptosis ↑ In injury models, mitochondrial dysfunction often ↓ G Intrinsic apoptotic cell death Strong recurring preclinical mechanism; cancer selectivity depends on dose and model.
4 Angiogenesis and endothelial migration VEGF-linked angiogenesis ↓; invasion ↓; migration ↓ Endothelial migration and tube formation ↓ (model-dependent) G Anti-angiogenic and anti-metastatic pressure Important for colorectal xenograft and endothelial assay interpretation; may be therapeutically relevant but exposure-limited.
5 NF-κB inflammatory signaling NF-κB-linked survival and cytokine tone ↓ (context-dependent) Inflammatory cytokine signaling ↓ R/G Inflammation-linked tumor support reduction More robust as an anti-inflammatory mechanism than as a standalone cancer-killing mechanism.
6 ROS and mitochondrial oxidative stress ROS ↑ can contribute to apoptosis (high concentration only) Oxidative stress ↓ in many toxic injury models R/G Context-dependent redox modulation antioxidant or pro-oxidant; direction depends on cell type, injury context, and concentration.
7 NRF2 cytoprotection ↔ or context-dependent; may be undesirable if it protects malignant cells NRF2/HO-1/NQO1 ↑ in injury-protection models G Secondary antioxidant-response modulation NRF2 is not a core anticancer mechanism for BCP; tag as secondary/contextual rather than primary.
8 Chemosensitization Cisplatin response ↑; apoptosis ↑; resistance signaling ↓ (model-dependent) Normal-cell toxicity data are insufficient for oncology combinations G Adjunct sensitization Preclinical evidence supports a sensitizer hypothesis, but there is no clinical cancer validation.
9 Radiosensitization Radiation response ↑ in colorectal cancer cells (model-dependent) Normal-tissue radioprotection versus radiosensitization is unresolved G Potential radiation adjunct Recent evidence is early and should be tagged as preliminary, not established.
10 Glycolysis and HIF-1α ↔ limited direct oncology evidence ↔ not a primary established axis G Not a core mechanism Do not add strong HIF-1α or glycolysis tags unless future product-specific cancer evidence supports them.
11 Clinical Translation Constraint Effective in-vitro exposure may exceed practical dietary exposure Food-use safety does not establish therapeutic-dose safety G PK and evidence limitation Key constraints are bioavailability, formulation, dose, tissue exposure, cancer-type heterogeneity, and lack of oncology trials.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr
PPARγ, Peroxisome proliferator-activated receptor gamma (PPAR-γ or PPARG): Click to Expand ⟱
Source:
Type:
Peroxisome proliferator-activated receptor gamma (PPAR-γ) is a type of nuclear receptor that plays a crucial role in regulating various biological processes, including glucose metabolism, lipid metabolism, and inflammation. It is primarily expressed in adipose tissue, but it is also found in other tissues, including the colon, breast, and prostate.
PPAR-γ has been shown to have both tumor-suppressive and tumor-promoting effects, depending on the type of cancer and the context. In some cancers, activation of PPAR-γ can inhibit cell proliferation and induce apoptosis, while in others, it may promote tumor growth.
PPARγ
– Plays a central role in adipogenesis, lipid storage, and insulin sensitivity.
– Widely expressed in adipose tissue, but also present in colon, breast, and immune cells.
– In addition to metabolic functions, PPARγ regulates cell differentiation, apoptosis, and has anti-inflammatory effects.
– Ligand binding (such as endogenous fatty acids or synthetic agonists like thiazolidinediones) alters transcriptional programs impacting cell cycle and survival.

– In many cases, PPARγ is expressed in tumor cells, and its activation has been linked to induction of differentiation and growth arrest.
– However, expression levels can differ based on tumor subtype, with some studies reporting elevated levels while others note reductions in aggressive tumors.
– Crosstalk with other signaling pathways (e.g., Wnt/β-catenin, MAPK) can alter PPARγ's net effect in cancer cells.
Scientific Papers found: Click to Expand⟱
6519- BCP,    beta-Caryophyllene: A Sesquiterpene with Countless Biological Properties
- Review, Nor, NA
*CB2 / CNR2↑, *Inflam↓, *iNOS↓, *IL1β↓, *IL6↓, *TNF-α↓, *NF-kB↓, *COX1↓, *COX2↓, *PPARα↑, *PPARγ↑, *BioEnh↑,
6515- BCP,  Xan,    Advancing Brain Health Naturally: β-Caryophyllene and Xanthohumol as Neuroprotective Agents
- Review, AD, NA
*neuroP↑, *BioAv↝, *CB2 / CNR2↑, *Inflam↓, *iNOS↓, *IL1β↓, *IL6↓, *TNF-α↓, *NF-kB↓, *COX1↓, *COX2↓, *PPARα↑, *PPARγ↑, *ROS↓, *tau↓, *NRF2↑, *HO-1↑, *AChE↓, *BChE↓, *BioAv↓,
6504- BCP,    β-Caryophyllene Induces PPARγ-Mediated Apoptosis and Enhances the Radiosensitivity in Colorectal Cancer Cells
- in-vitro, CRC, CT26 - in-vitro, CRC, HCT116
RadioS↑, TumCCA↑, γH2AX↑, DNAdam↑, p‑Akt↓, cycD1/CCND1↓, PPARγ↑, Bax:Bcl2↑, Casp3↑, Apoptosis↑,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis(tgid=4) ⓘ

PPARγ↑, 1,  

Cell Death(tgid=5) ⓘ

p‑Akt↓, 1,   Apoptosis↑, 1,   Bax:Bcl2↑, 1,   Casp3↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycD1/CCND1↓, 1,   TumCCA↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

RadioS↑, 1,  
Total Targets: 10

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

HO-1↑, 1,   NRF2↑, 1,   ROS↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

PPARα↑, 2,   PPARγ↑, 2,  

Cell Death(tgid=5) ⓘ

iNOS↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CB2 / CNR2↑, 2,   COX1↓, 2,   COX2↓, 2,   IL1β↓, 2,   IL6↓, 2,   Inflam↓, 2,   NF-kB↓, 2,   TNF-α↓, 2,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 1,   BChE↓, 1,   tau↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↝, 1,   BioEnh↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 2,  

Functional Outcomes(tgid=23) ⓘ

neuroP↑, 1,  
Total Targets: 22

Scientific Paper Hit Count for: PPARγ, Peroxisome proliferator-activated receptor gamma (PPAR-γ or PPARG)
3 Beta-Caryophyllene
1 xanthohumol
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:401  Target#:259  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page